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Abstract
Background: Lignosus rhinocerus (L. rhinocerus), which is known locally as Tiger Milk mushroom, is traditionally used
in the treatment of asthma by indigenous communities in Malaysia. However, to date, its efficacy on asthma has
not been confirmed by scientific studies and there is also sparse information available on its active constituents. In
this study, the volatile constituent of L. rhinocerus hot water extract was investigated using gas chromatography
mass spectrometry (GC-MS). The potential effects of L. rhinocerus extract for anti-asthmatic activity was further
investigated on ovalbumin (OVA)-sensitized asthmatic Sprague Dawley rats.
Methods: Sequential extraction using five solvents (petroleum ether, diethyl ether, hexane, ethyl acetate and
methanol) was conducted prior to GC-MS analysis. Male Sprague Dawley rats were divided into the following
four groups of five animals each: 1) normal rats, 2) sensitization plus OVA-challenged rats 3) sensitization plus
OVA-challenged with L. rhinocerus treatment and 4) sensitization plus OVA-challenged with dexamethasone
treatment. The levels of immunoglobulin E (IgE) in the serum and T-helper 2 cytokines, including interleukin (IL)-4, IL-5
and IL-13, in bronchoalveolar lavage fluid (BALF), as well as eosinophil infiltration in the lungs, were investigated.
Results: GC-MS analysis revealed the presence of five main groups (alkane, fatty acids, benzene, phenol and
dicarboxylic acid) with a total of 18 constituents. Linoleic acid (21.35 %), octadecane (11.82 %) and 2,3-dihydroxypropyl
elaidate (10.47 %) were present in high amounts. The extract significantly ameliorated the increase in total IgE in serum
and IL-4, IL-5 and IL-13 levels in BALF and also effectively suppressed eosinophils numbers in BALF while attenuating
eosinophil infiltrations in the lungs.
Conclusion: L. rhinocerus hot water extract has the potential to be used as an alternative for the treatment of
acute asthma.
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Background
Asthma affects 300 million people worldwide and is a
result of a complex interplay between genetic and en-
vironmental factors [1]. Allergic asthma is a chronic
disease characterized by recurrent wheezing, shortness
of breath, chest tightness and coughing. The airway dis-
order is commonly characterized by airway eosinophilia
infiltration, increased serum immunoglobulin E (IgE)
and T-helper 2 (Th2) cytokine levels such as interleukin
(IL)-4, IL-5 and IL-13 [2], as well as excessive produc-
tion of airway mucus.
The Th2-dominated response is initially triggered
when an airway allergen is taken by the dendritic cells
and presented to specific Th cells by means of major
histocompatibility complex (MHC) class II, thus stimu-
lating the immunological synapse. Activated allergen-
specific Th cells then polarize into Th1 or Th2 effector
populations, differentiate and expand into a Th2 sub-
population. The activated Th2 cells function in recruit-
ing and activating cytokines, including IL-4, IL-5 and
IL-13, following stimulation of eosinophils. IL-4 cyto-
kines have been reported to cause class switching of B
cells, resulting in IgE synthesis, which is involved in
mast cell degranulation [3]. The key role of IL-5 cyto-
kines includes their involvement in the growth and
differentiation of bone marrow eosinophils, as well as
their release into the peripheral circulation [4]. Add-
itionally, IL-5 also increases the activity of eosinophil
recruitment, activation and survival at the sites of in-
flammation [5]. IL-13, which is known as the “central
mediator of allergic asthma,” plays an important role
in directing the allergic response in asthmatic patients
[6]. Various studies are therefore primarily focused on
products that have the potential to reduce IgE, IL-4,
IL-5, IL-13 and eosinophils as therapeutic targets for
asthma treatment [7–10].
Current asthma medications are mainly based on
steroids and other types of anti-inflammatory drugs
[11]. Among the available drugs, inhaled corticoste-
roids (ICSs) are very effective, as they suppress chronic
airway inflammation in patients with asthma [12]. ICSs
are generally considered harmless, though persistent
use of ICSs at higher doses often leads to various systemic
and local side effects [13], some of which include candid-
iasis, osteoporosis, growth retardation, cataracts and
pharyngitis [14]. Thus, a safer alternative for the man-
agement of asthma is needed.
Lignosus rhinocerus (L. rhinocerus) from the Polypor-
aceae family is a wild mushroom exclusive to Malaysia.
Locally known as “cendawan susu rimau” or “Tiger
milk mushroom”, this unique mushroom is one of the
reported 38 available types of edible mushrooms in
Malaysia used for medicinal purposes by rural and in-
digenous communities [15]. The tuber is purported to
contribute the most medicinal value, and the indigen-
ous populations in Peninsular Malaysia utilise it to
treat diseases such as asthma, fever, breast cancer,
stomach cancer and food poisoning, as well as to heal
wounds [15, 16]. Previous studies have demonstrated
anti-proliferative activities [17] and immunomodula-
tory properties [18] of this mushroom sclerotial. A recent
study by Lee et al. [19] reported anti-acute inflammatory
properties of sclerotial powder of L. rhinocerus using
carrageenan-induced paw oedema model in rats. In
addition, the study also demonstrated a potent inhibition
of TNF-α production by the high-molecular-weight frac-
tions of the sclerotial powder of L. rhinocerus. However, to
date, no studies have been reported on the anti-asthmatic
properties of L. rhinocerus in airway inflammation models.
Thus this study reported anti-asthmatic effects of L.
rhinocerus sclerotial extract in ovalbumin-induced air-
way inflammation of the rodent model and the profile
of volatile constituents of the mushroom extract by
GCMS analysis.
Methods
Preparation of L. rhinocerus hot water extract
Sclerotia of L. rhinocerus cultivar TM02 was obtained
in dried powdered form from Ligno Biotech Sdn. Bhd.
(Selangor, Malaysia). The powder was subjected to hot
water extraction using a soxhlet for 24 h and was further
concentrated using a rotary evaporator (Unimax1010, Hei-
dolph, Germany) before being freeze-dried in a freeze drier
(Ilshin BioBase, Gyeonggi-do, Korea).
Liquid-liquid extraction
A sequential liquid-liquid extraction was performed
using 1) petroleum ether, 2) diethyl ether 3) hexane, 4)
ethyl acetate and 5) methanol. The selected solvents
ranged in polarity starting from non-polar (petroleum
ether, diethyl ether and hexane) to more polar solvents
(ethyl acetate and methanol) to take advantage of their
different properties.
Briefly, 1 ml of petroleum ether was added to the
capped glass tube containing 1 g of L. rhinocerus extract.
The mixture was then vortexed for 1 min using a vortex
mixer (Westbury, New York, USA), followed by centrifu-
gation (Centrifuge Universal 32R, HettichZentrifugen,
Germany) at 700 × g for 5 min. The supernatant was as-
pirated before being transferred (100 μl) to a new auto-
sampler vial for GC-MS injection. The residue was used
for subsequent extraction using diethyl ether followed by
hexane, ethyl acetate and finally, methanol, as previously
described for petroleum ether. Following extraction by
each solvent type, the samples were individually injected
into the GC-MS system in duplicate. Each sample was
analyzed against a blank organic solvent containing a
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similar type of organic solvent used in the extraction
process each time.
GC-MS analysis
GC-MS analysis was performed on an HP6890 GC coupled
with a HP5973 mass spectrometer (Hewlett Packard, CA,
USA). The column was a HP-5MS fused-silica capillary
column (50 m x 0.25 mm i.d.; 0.25-μm film thickness)
with helium as the carrier gas, and it was run at a con-
stant pressure of 9.78 psi. Injection was conducted
using a splitless mode at an injector temperature of
250 °C. The oven temperature was ramped from 40 °C
to 280 °C (1-min hold) at a rate of 25 °C/min. The oven
temperature was held at 310 °C for 6 min for each ana-
lysis. The total run time for each sample was approxi-
mately 28 min. The GC-MS interface temperature was
set to 280 °C. MS mode was used during analytical
scanning from 20 to 650 atomic mass units (amu). The
ion source temperature was set at 250 °C.
The blank was injected first each time, followed by the
sample injection. The chromatograms obtained from the
total ion current (TIC) were integrated without any cor-
rection for co-eluting peaks, and the results were
expressed as total abundance. The TIC peaks and chro-
matograms were analyzed using an Agilent Technologies
7890A GC system with 597C VL MSD. All peaks were
identified based on mass spectral matching (≥ 90 %)
from both the National Institute of Standards and Tech-
nology (NIST) and Wiley libraries. Only compounds with
90 % or greater spectral matching accuracy were reported.
Animals
Ethical approval was obtained from Animal Ethics
Committee Universiti Sains Malaysia. Male Sprague
Dawley rats (age between 6 and 8 weeks; 200–250 g in
weight) were used for this experiment. The rats (n = 20)
were housed in polystyrene cages in an air-controlled
room. All animals were maintained at the animal house,
and tap water was allowed ad libitum. The animals were
acclimatized to the experimental environment prior to
commencement of the study.
Sensitization, airway challenge and treatment
The rats were divided into the following four groups of
five animals each: (1) normal rats, (2) sensitization plus
1 % OVA challenge or “untreated group,” (3) sensitization
plus 1 % OVA challenge with oral L. rhinocerus treatment
(500 mg/kg per body weight) and (4) sensitization plus
1 % OVA challenge with intraperitoneal (ip) dexametha-
sone treatment (3 mg/kg per body weight). Sensitization
on days 1 and 14 was conducted with a 2 × 1 ml i.p. injec-
tion of 10 mg/ml OVA (Nacalai Tesque, Kyoto, Japan) +
100 mg/ml alum (aluminium hydroxide) (Sigma, MO,
USA) in phosphate buffered saline (PBS) (based on the
modified method of Makhlouf and Hafez, [20]). An
additional 50 ng/ml of Bordetella pertussis (Sigma, MO,
USA) was also prepared with the solution as adjuvant.
On day 23, the rats were challenged with 1 % OVA
aerosol for 20 min/day for 7 days using an ultrasonic
nebulizer (Mabist mist, Illinois, USA) and orally admin-
istered by gavage with 500 mg/kg per body weight of L.
rhinocerus extract for 7 days. On day 30, 24 h after the
final challenge, the rats were anesthetized with keta-
mine (100 mg/kg) and xylazine (10 mg/kg), and blood
was collected by cardiac puncture.
Eosinophils and inflammatory cell count
Following sacrifice, bronchoalveolar lavage fluid (BALF)
was obtained using an endotracheal tube by instilling
and aspirating the trachea with PBS solution. BALF was
centrifuged at 500 × g for 5 min, and the pellet was re-
suspended with PBS. The total inflammatory cell num-
ber was quantified by counting the number of cells from
at least five squares of the haemocytometer after exclud-
ing dead cells stained with trypan blue.
Measurement of total IgE in BALF
The total IgE was measured with a specific rat ELISA kit
(Abnova, Heidelberg, Germany) according to the manu-
facturer’s instructions. IgE levels in each sample were
measured from optical density readings at 450 nm
followed by calculation based on a standard curve that
was generated using recombinant IgE.
Measurement of Th2 cytokines in BALF
An enzyme-linked immunosorbent assays (ELISA) was
performed according to the manufacturer’s instructions.
IL-4, IL-5 and IL-13 in BALF were measured using spe-
cific rat IL-4, IL-5 and IL-13 ELISA kits (CusaBio,
Hubei, China). The bound enzyme that was proportional
to the respective cytokines concentration was investi-
gated at absorbance of 450 nm. Cytokine concentrations
were calculated from standard curves that were gener-
ated using respective recombinant interleukins.
Lung tissue histology
The lungs were removed, rinsed with PBS, weighed and
fixed in 10 % formalin overnight for immunohistochem-
istry analysis. The lung tissue was embedded in paraffin
and cut into 4-μm thickness sections, followed by
haematoxylin and eosin staining for lung inflammation
scoring. The tissue was subsequently mounted and
cover-slipped with di-n-butyl phthalate in xylene (DPX)
mounting medium. The infiltration intensity at peribron-
chial and perivascular inflammatory spaces was scored
as the approximate number of cell layers around vessels
or bronchioles following criteria adapted from Tournoy
et al. [21]. Whole lung sections were assigned using a
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reproducible scoring system developed for a murine
model (Curtis, et al., [22]). The scoring system ranges
between 0 to 4 as follows, indicating inflammation sever-
ity based on no inflammation, the presence of occasional
cuffs, the presence of a thin layer or presence of inflam-
matory cells surrounding the peribronchial/perivascular






For each rat, randomly distributed airway sections in
the lung were analysed, and their mean scores were cal-
culated. The inflammation present was evaluated with a
double-blinded scoring method. Quantitative analysis of
the lung inflammation score was performed using a
Mirax Image viewer (Carl Zeiss, Jenna, Germany).
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). Statistical significance (p < 0.05) was determined by
a one-way ANOVA followed by Scheffe’s post hoc cor-
rection and inflammation scores were analysed with
Wilcoxon-Mann Whitney test using Statistical Program
for Social Science (SPSS) version 22.0 (New York, USA).
Results
GC-MS analysis of the volatile constituent of L. rhinocerus
Five major groups, including alkanes (53 %; estimated
weight fraction of 53 mg) and fatty acids (36 %), were
detected (Fig. 1). Overall, eighteen constituents were ex-
tracted by the five solvents (petroleum ether, diethyl
ether, hexane, ethyl acetate and methanol) (Fig. 2).
The highest numbers of constituents (eight compounds)
were reported from non-polar (hexane) extraction followed
by ethyl acetate (6 compounds), petroleum ether (5
compounds), diethyl ether (3 compounds) and methanol (2
compounds) extractions (Table 1). The constituent with the
greatest proportion in L. rhinocerus hot water extract was
linoleic acid (21.35 %), followed by 2,3-dihydroxypropyl
elaidate (11.82 %) and octadecane (10.47 %). The chemical
structures and molecular formula for the detected volatile
constituents are described in Table 2.
Inhibition effects of L. rhinocerus on airway inflammation
A preliminary study was conducted prior to the present
investigation to optimize L. rhinocerus dosages and the
dose used in the sensitization protocol that was suitable
for the anti-asthmatic study. Based on this finding, a
dose of 500 mg/kg of L. rhinocerus is more effective in
reducing asthma-related parameters when compared to
low (125 mg/kg) and medium (250 mg/kg) dosages (un-
published data) and was therefore selected for the study.
A previous toxicity study indicated that 1000 mg/kg of
L. rhinocerus extract fed orally to rats did not cause any
adverse effects, and it is therefore considered to be safe
[23]. The sensitization method was modified from a previ-
ous study [20] based on similar preliminary optimization
study, hence i.p. sensitization with the additional adjuvant
of Bordetella pertussis and 7 days of challenge or treat-
ment was suitable to establish the expected allergic model.
Our study targeted serum IgE detection, while Th2
cytokine detection was conducted in BALF. As in asth-
matic models, airway obstructions and difficulties in
breathing are assumed to result from the responses of
immunoglobulins and cytokine levels, which lead to
worsening of asthma symptoms. Eosinophils are also
found in large numbers within the submucosa and epi-
thelium in the allergic model. Most allergic mediators
are stimulated by IgE and are released into the blood
stream in response to inflammatory reactions [9]. In
addition, BALF biofluid is widely accepted as a reliable
sample with which to determine the composition of se-
creted pulmonary proteins and the products of activated
cells. Therefore, in this study we aimed to investigate
OVA-induced IgE detection in serum, while Th2 cyto-
kines were detected in BALF.
High numbers of inflammatory cells in BALF indicate
inflammation and an allergic condition. The level of in-
flammatory cell eosinophil infiltration in BALF was
significantly reduced in the L. rhinocerus and dexa-
methasone groups compared to the untreated group
(Fig. 3). However, the reduction observed with dexa-
methasone was slightly more prominent when com-
pared to L. rhinocerus. The untreated group had the
highest level of eosinophils, indicating marked induc-
tion of allergic asthma. The level of eosinophils in the
untreated group was also significantly elevated when
compared to the normal group.Fig. 1 Groups of compounds present in L. rhinocerus
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Similarly, there was also a significant reduction in the
mean serum IgE levels among animals receiving L. rhi-
nocerus or dexamethasone when compared to the
untreated group (Fig. 4). The reduction in the levels of
IgE and Th2 cytokines indicate successful asthmatic
treatment. In comparison, the IgE levels in the
untreated group were significantly elevated when com-
pared to the normal group.
The levels of IL-4 (Fig. 5a) and IL-5 (Fig. 5b) were sig-
nificantly reduced in the L. rhinocerus and dexamethasone
groups when compared to the untreated group. There was
also a reduction in the IL-13 level among animals
Fig. 2 Volatile compounds detected in L. rhinocerus and their relative percentages
Table 1 Volatile compositions of L. rhinocerus following extraction using various solvents and their respective retention times, RT (min)
Compounds P.E R.T D.E R.T HX R.T E.A R.T MTL R.T Relative %
Octadecane ✓ 10.31 ✓ 13.61 ✓ 9.43 10.47
Heptadecane ✓ 12.76 ✓ 12.79 ✓ 8.99 9.29
Benzene, 1,3-bis (3-phenoxyphenoxy) ✓ 3.18 3.43
Phytane ✓ 9.86 2.30
Docosane ✓ 12.05 3.54
Phthalic acid ✓ 9.81 1.10
2,4-Dimethyl-1-heptene ✓ 3.88 0.36
1,3-Di-tert-butylbenzene ✓ 6.77 ✓ 6.76 2.38
Heneicosane ✓ 14.5 6.22
Tricosane ✓ 15.47 4.00
1-Chlorooctadecane ✓ 16.48 6.69
Tritetracontane ✓ 10.83 2.25
Eicosane ✓ 10.84 ✓ 10.32 4.77
Nonadecane ✓ 9.86 2.61
2,3-Dihydroxypropyl elaidate ✓ 28.89 11.82
Oleic acid ✓ 27.54 2.55
Linoleic acid ✓ 3.20 21.35
Ethylbenzene ✓ 4.08 4.87
Total percentage 100.00
PE petroleum ether, DE diethyl ether, HX hexane, EA ethyl acetate, MTL methanol
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receiving L. rhinocerus and dexamethasone. However, the
reduction in IL-13 observed among animals receiving L.
rhinocerus was not statistically significant when compared
to the untreated group (Fig. 5c). The levels of all Th2 cyto-
kines in the untreated groups were significantly elevated
when compared to the normal group.
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Haematoxylin and eosin staining was performed on
the lung tissues to analyze the effects of L. rhinocerus
extract on the histological feature of asthma. The lung
tissue section of ovalbumin-induced asthmatic rats was
characterized by the presence of dense peribronchial in-
flammation due to leukocyte infiltration when compared
with the normal tissue (Fig. 6a). Substances that can at-
tenuate this inflammation indicate that they are effective
anti-asthmatic agents. Histopathological findings further
confirmed that there was significant reduction in the se-
verity of eosinophil cell inflammation with significantly
reduced cells forming eosinophil layers/rings in both the
L. rhinocerus and dexamethasone groups. In addition,
the inflammation score indicated that both the L. rhino-
cerus and dexamethasone groups showed significantly
reduced inflammation when compared to the untreated
group (Fig. 6b).
Discussion
Our study is the first to elucidate the composition of hot
water extract of L. rhinocerus widely used in the trad-
itional treatment of asthma. Alkanes were the major
group found to be present, while linoleic acid was the
major constituent detected. To our knowledge, our study
is also the first to confirm the airway inhibition effects
of L. rhinocerus.
The GC-MS analysis was conducted following a se-
quential extraction method that employs both polar and
non-polar properties of solvents in separating com-
pounds based on polarity. In this study, a simple liquid-
liquid extraction method is beneficial because it does
not involve a heating process, which minimizes damage
to the volatiles and can prevent the formation of other
artefacts [24, 25]. This sequential extraction conserves
the amount of volatiles as well as selectively improves
the process and the recovery of different types of ex-
tracts from analogous materials. The compounds were
Fig. 5 The effect of L. rhinocerus extract on the cytokines (a)
IL-4, (b) IL-5 and (IL-13) levels in BALF. Normal; untreated, OVA-
sensitized/challenged rats; L. rhinocerus extract + OVA-sensitized/
challenged rats; dexamethasone +OVA-sensitized/ challenged rats.
Values are expressed as the means ± SD (n = 5/group). *Significantly
different from untreated
Fig. 4 The effect of L. rhinocerus extract on serum IgE levels. Normal;
untreated, OVA-sensitized/challenged rats; L. rhinocerus extract +
OVA-sensitized/challenged rats; dexamethasone + OVA-sensitized/
challenged rats. Values are expressed as the means ± SD (n = 5/group).
*Significantly different from untreated
Fig. 3 The effect of L. rhinocerus extract on the recruitment of
inflammatory cells in BALF. Normal; untreated, OVA-sensitized/challenged
rats; L. rhinocerus extract + OVA-sensitized/ challenged rats;
dexamethasone + OVA-sensitized/ challenged rats. Values are
expressed as the means ± SD (n = 5/group). *Significantly different from
untreated. #Significantly different within treatment
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selected based on spectral library matching to the NIST
and Wiley libraries.
Most of the compounds detected were from the alkane
group. In comparison, a study of other types of medi-
cinal mushrooms such as Termitomyces sp. and Termito-
myces microcarpus prepared from petroleum ether crude
extracts reported the presence of small amounts of octa-
decane (0.64 %) and heptadecane (1.01 %) [26], which
are alkanes. Another researcher reported the presence of
octadecane (0.15 %) in Trichodermaharzianum following
GC-MS analysis [27]. However, our study detected the
presence of higher amounts of octadecane (10.47 %) and
heptadecane (9.29 %) in L. rhinocerus. Similar to our
study, a study on Agaricus bisporus comparing different
strains of mushrooms (strains 310 and 342) reported
high amounts of non-polar compounds such as octade-
cane (13.8 %) and nonadecane (14.4 %) in addition to
eicosane and heptadecane [28]. In addition, several stud-
ies [28–30] have reported fatty acids to be the predom-
inant constituent in mushrooms. Specifically, linoleic
acid has been detected to be the major constituent
(~65 %) of Schizophyllum commune and Lentinus edodes
[31], which is also reported in our study as the most
common compound (21.35 %). Similar to our study, the
Fig. 6 The effect of L. rhinocerus on airway inflammatory leukocyte infiltration in the peribronchiole region and perivascular connective tissue. (a)
Magnification 50×. Black arrows indicate the presence of infiltration with eosinophils/leukocytes surrounding the bronchiole. (b) Quantitative analysis
on the inflammation score with a subjective scale of 0–4 used to assess leukocyte infiltration in the lungs
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fatty acid profile of several Tricholoma species, such as
T. portentosum and T. terreum, also revealed the pres-
ence of linoleic acid (∼28 %) [32].
Linoleic acid is a known precursor of 1-octen-3-ol
(alcohol of fungi), which functions as the principal aro-
matic compound in most fungi [33–35]. A study on L.
rhinocerotis comparing mycelium of shaken cultures
and static cultures revealed the presence of 2.3-dihy-
droxypropyl elaidate compound (0.27–0.28 %) [36]. The
presence of a similar compound was also detected in
the spore lipids of Ganoderma lucidum (0.07 %) [37].
In our study, 2,3-dihydroxypropyl elaidate was reported
to be present at approximately 11.82 % and constituted
the second most common compound detected. In com-
parison, linoleic acid was compared in different parts of
A. bisporus mushroom and was reported to be present
in 12.2 % of the volume of the whole fresh sample, in
1.5 % of the stalks and in 0.8 % of the gills [38].
Linoleic acid was present in varying concentrations in
different types of mushrooms, and unique properties
were observed. In fact, such variations are key to under-
standing the aromatic and other medicinal properties.
Nonetheless, GC-MS analysis of L. rhinocerus revealed
compounds that were detectable and comparable with
other mushrooms types and plants [29, 39, 40], making
them both similar and different to plants of numerous
species and genus.
This study is the first to report on the inhibition ef-
fects of L. rhinocerus on airway inflammation in asth-
matic model. Asthmatic model of Sprague Dawley rat
was used in the study and dexamethasone was used as
a positive control as this compound is commonly used
as a potent inhibitor of airway inflammation and re-
modelling. The administration of corticosteroids has
been demonstrated to inhibit structural changes associ-
ated with airway fibrosis in animal models and is there-
fore widely utilized as a control in asthma studies [41].
In the context of the experimental design, all rats in
this study (except for the normal group) underwent
sensitization on days 1 (primary sensitization) and 14
(secondary sensitization). The purpose of an additional
sensitization step on day 14 is to ensure that the levels
of airway eosinophils do not revert back to the baseline,
as well as to avoid the development of tolerance. In
addition, these sensitizations were coupled with OVA
along with alum and Bordetella pertussis to enhance
Th2-dominated responses [42].
Generally, the activation, growth and differentiation of
eosinophils are conducted by Th2-dominated responses
[43]. It is reported that cytokines secreted by Th2 cells
can help in the recruitment and activation of eosinophils
in the nasal region. Eosinophil counts performed on
BALF in this study revealed that treatment with hot
water extract of L. rhinocerus has reduced the number of
eosinophils to 6.54 × 104 cells in BALF when compared
to the untreated group, which contained 8.34 × 104 cells;
this could indicate attenuated severity and possible with-
drawal in eosinophil infiltration along the submucosa
and epithelium regions. Groups of rats receiving hot
water extract of L. rhinocerus and dexamethasone treat-
ment had also significantly decreased the numbers of
total inflammatory cells in BALF. These decreases are
correlated with the level of cellular infiltration. Further-
more, the deterioration of inflammatory cell numbers in
BALF was confirmed by lung tissue histology, thus pos-
sibly be valuable in controlling the inflammatory pro-
cesses underlying exacerbation of allergic asthma. This
result is in accordance with the previous study that dem-
onstrated the reduction of eosinophils in OVA-treated
animals after treatments with herbal extract [8].
An early finding indicated that in sensitized individ-
uals, the nasal mucosa contains high level of IgE-binding
mast cells [44]. Upon sensitization, increasing numbers
of IgE-coated mast cells traverse the epithelium. During
the phase of allergen exposure or challenge, the IgE-
coated mast cells recognize the allergens deposited at
mucosal regions, and the mast cells then degranulate.
This leads to the release of mediators such as histamines
and leukotrienes, which are responsible for blood vessel
leakage to stimulate the sensory nerves leading to con-
gestion, airway inflammation and obstruction as well as
systemic reflexes such as sneezing [45]. Thus, reducing
IgE levels has been the major focus in combating
asthma. Accordingly, animals receiving hot water extract
of L. rhinocerus had significantly reduced IgE levels
(14.88 ng/ml) when compared to the untreated group
(16.29 ng/ml). A recent study also reported that another
type of mushroom polysaccharide from A. camphorata
has similar anti-asthmatic effects shown by reducing IgE
levels in an animal model of asthma [46].
In our study, it was noted that hot water extract of L.
rhinocerus significantly reduced IL-4 levels in BALF.
This is supported by a study using murine allergen chal-
lenged models where intranasal chitin polysaccharide
components of fungal cell decreased IL-4 (16.22 pg/ml)
production compared to untreated group (23.07 pg/ml)
in vivo [47, 48]. Moreover, Th2 cytokine concentration
levels of IL-5 (38.82 ng/ml) and IL-13 (80.54 pg/ml)
were also reduced when hot water extract L. rhinocerus
was used to treat sensitized rats in comparison with un-
treated groups (42.79 ng/ml and 83.69 pg/ml), respect-
ively. Similarly, both IgE levels in the serum and Th2
cytokines in BALF were also reduced by dexamethasone.
However, the reduction observed in the IL-13 levels due
to L. rhinocerus administration was not significant,
which may illustrate the varying effects of L. rhinocerus
extract on IL-13 regulation. Interestingly, IL-13 has been
reported to potentially have independent roles from
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eosinophils, IgE, IL-4 and IL-5 [49]. It has been reported
that the production and high activity of eosinophils, the
hallmark of asthma, was not affected despite inhibition
of IL-13 [49]. However, the potential independent role of
IL-13 in prompting the complete allergic asthmatic
phenotype has been underlined. In a study on IL-13-
dependent airway hyper responsiveness (AHR), it was
revealed that the mechanisms are independent of IgE
and eosinophils in mice [6].
The lung histopathology study further confirmed how
structural changes or responses involving lung tissues
further contribute to asthma. Indications of such as
high leukocytes or eosinophil infiltration at regions
around the peribronchial and perivascular space in the
bronchioles are important keys that point to such a se-
vere condition [22]. Consistent with previous findings
regarding immunoglobulin and Th2 cytokines, both the
hot water extract of L. rhinocerus and dexamethasone
were noted to reduce the number of eosinophil cells in-
filtrating into lungs tissue. A similar histological study
on A. Camphorata also reported attenuation of lung in-
flammatory leukocytes in OVA-sensitized animals [45].
Relief of bronchoalveolar inflammation in a murine
model of airway sensitivity has also been reported in a
histology study that used another type of mushroom
i.e., Ganoderma tsugae (G. tsugae) as a possible treat-
ment for allergic asthma [50].
Several findings further confirm that immune disor-
ders are attributable to the collapse of the system that
controls the balance between levels of Th1 to Th2
cells. In fact, diseases such as leprosy, allergic asthma
and multiple sclerosis are associated with aberrant
Th1 and Th2 polarizations. Th2 cells are also strongly
implicated in atopy and allergic inflammation. A. cam-
phorata polysaccharides, for instance, are potential in-
ducers of Th1-type cytokines such as tumour necrosis
factor and interferon but not of Th2 cytokines, which
have successfully been proven to reduce asthmatic
conditions [46]. The importance in discovering and
identifying new drugs that are safe and effective and
have minimal side effects has made the medicinal
properties of plants more valued and thereby more
widely explored. Our study demonstrated that treat-
ment of OVA-induced airway inflammation among
Sprague Dawley rats treated with hot water extract of
L. rhinocerus significantly reduced allergic asthma pa-
rameters i.e., IgE level, Th2 cytokines, eosinophil
count and eosinophil infiltration in the lungs.
Various speculations denote the potential anti-
asthmatic effects of L. rhinocerus. Investigating the
roles of fatty acids in reducing asthma symptoms has
been gaining high attention in studies of animal
models as well as children [51, 52]. Interestingly, a
previous chemical study on L. rhinocerotis revealed
that major compounds such as fatty acids are present
[36].
Polyunsaturated fatty acids (PUFA) have been found
to have potential anti-inflammatory properties with
fewer side effects, and they are claimed to be mildly
beneficial for the treatment of allergic conditions such
as asthma and atopic dermatitis [53]. In fact, previous
studies [53, 54] have proven that PUFAs are closely as-
sociated with enhanced lung function and reduced
asthma symptoms. It has been shown that n-3 PUFAs
suppress a major mediator of asthma known as leuko-
triene synthesis [51]. The role of such fatty acids is also
associated with the modulation of prostaglandin metab-
olism, which is the primary cause of exacerbated condi-
tions of allergic asthma. It has been proven that the
anti–asthmatic potential of Zanthoxylum bungeanum is
due to the presence of some phytochemical com-
pounds, specifically those rich in linoleic acids [54].
Therefore, it is plausible that the presence of high con-
centrations of linoleic acid in L. rhinocerus which is
also one of the main key constituents, contributes to
the anti-asthmatic effect. Nevertheless, this should be
confirmed in a further study.
It should be noted that there may be differences in the
type of detectable volatile compounds present in fresh L.
rhinocerus in contrast to the cultivated sample used. In
addition, the spectral library matching performed in this
study during the detection of volatile compounds pro-
vides preliminary presumptive data; therefore, future
studies that contribute to the utilization of authentic
standards should be conducted to further confirm our
findings. Confirming the presence of compounds with
long-chain fatty acids can be further supported by add-
itional methylation steps as is also recommended by
Mendez et al. [55]. Moreover, this study only focused on
volatile compounds of L. rhinocerus as these compounds
are reported to be the intermediate or end products of
diverse metabolic pathways of various classes [27]. Iden-
tification of non-volatile and semi-volatile organics,
which are more suitable for investigation using liquid
chromatography/mass spectrometry, was not performed
at this point of the study.
Conclusion
Alkanes were the major group present in hot water extract
of L. rhinocerus, while linoleic acid was the major con-
stituent detected. L. rhinocerus showed anti-asthmatic
effects in vivo as confirmed by the decreased levels of IgE
and Th2 cytokines responsible for eosinophils recruit-
ment, as well as the attenuation of eosinophil infiltration
in the lungs. Thus, L. rhinocerus has the potential to be a
promising alternative or adjuvant to the current drugs
used for the management of allergic asthma.
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